Riskpilot← Back to searchSign inGet full accessCitomed Oy
OYActiveY-tunnus 0733952-5Rovastintie 40Wholesale of pharmaceutical and medical goods · NACE 4646Est. 1989— employees
Revenue 2024
EUR 621K
-1% vs 2023
EBITDA margin
23.6%
-1% vs 2023
Equity ratio
8.2%
Financial strength
Net profit 2024
EUR 65K
-4% vs 2023
| Revenue | EUR 621K | -1% |
| EBITDA | EUR 147K | -1% |
| Net profit | EUR 65K | -4% |
| Total assets | EUR 988K | -4% |
| Equity | EUR 81K | +16% |
| Employees | — | — |
Legal name
Citomed Oy
Y-tunnus number
0733952-5
Legal form
Osakeyhtiö
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
13. maaliskuuta 1989
Share capital
EUR 2 523
Employees
—
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja ja toimitusjohtaja kumpikin yksin ja hallituksen jäsenet kaksi yhdessä
Company purpose
Yhtiön toimiala on terveydenhoitoon liittyvien tuotteiden ja laitteiden osto ja myynti. Työvoiman vuokraus sekä koneiden ja kiinteistöjen osto, myynti ja vuokraus sekä kaikki muu laillinen liiketoiminta.
Address
Rovastintie 40
Phone
+3580405242365
Email
timo.palander@citomed.fi
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 1 088 | 1 177 | 888 | 630 | 621 |
| Staff expenses | −0 | −0 | — | −0 | −5 |
| EBITDA | 345 | 337 | 211 | 148 | 147 |
| Depreciation & amort. | −41 | −79 | −81 | −54 | −59 |
| EBIT | 304 | 258 | 130 | 94 | 88 |
| Net financials | −7 | −8 | −4 | −9 | −7 |
| Profit before tax | 297 | 250 | 125 | 85 | 81 |
| Tax | 21 | 50 | 27 | 17 | 16 |
| Net profit | 276 | 200 | 99 | 67 | 65 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 878 | 1 238 | 1 117 | 1 028 | 988 |
| Equity | 569 | 724 | 103 | 70 | 81 |
| Long-term debt | 189 | 165 | 110 | 134 | 85 |
| Short-term debt | 120 | 349 | 904 | 825 | 822 |
| Total debt | 309 | 514 | 1 014 | 958 | 907 |
EBITDA margin
23.6%
This company
15.8%
Market median
+49% vs market
20202024
Equity ratio
8.2%
This company
38.2%
Market median
-79% vs market
20202024
Return on equity
79.7%
This company
18.4%
Market median
+333% vs market
20202024
Net profit margin
10.4%
This company
8.1%
Market median
+28% vs market
20202024
Asset turnover
0.63×
This company
1.12×
Market median
-44% vs market
20202024
Debt / equity
11.15×
This company
0.62×
Market median
-1698% vs market
20202024
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
AM Chief Executive Officer | Chief Executive Officer | 2008 |
SR | Audit | 2023 |
HJ Deputy auditor | Deputy auditor | 2023 |
| Former (1) | ||
JE | Audit | 2021 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairperson | 2008 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Citomed Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Juha Erkki Väinö Kerimaa | Audit | 0 companies |
| Anne Marjatta Palander | Chief Executive Officer | 0 companies |
| Stefan Rolf Axel Wiklund | Audit | 0 companies |
| Hans Jan Anders Jåfs | Deputy auditor | 0 companies |
| Timo Pekka Palander | Chairperson | 0 companies |